Welcome to the Abel Lab!

Care Delivery Research for Patients with Blood Cancers 

The Abel Lab at Dana-Farber Cancer Institute applies health services research methods to understand the experiences of patients with blood cancers and develop interventions to improve care.

We are interested in evaluating how cancer and its therapies affect outcomes such as function and quality of life. Through our work and collaboration with researchers in oncology, hematology, geriatrics, ethics, and energy balance, we aim to ameliorate the impact of hematologic malignancies and their treatment from diagnosis to the end of life.

Dr. Abel discusses the care delivery and bioethics impact of telemedicine implementation at Dana-Farber with Dr. Wagner, the Medical Director of Adult Ambulatory Oncology.

Explore this website to learn about the Abel Lab’s current research and former projects.

• A commentary on Dr. Hantel's recent analysis regarding modernizing eligibility criteria for AML trials was published in Blood.

   

• Dr. Marron and Dr. Abel's article, "How I approach clinical ethics consultation in hematology," was published in Blood.

   

• A new manuscript from the NHLBI-MDS National MDS Study team and collaborators from the Abel Lab on variability in myelodysplastic syndromes was published in the American Journal of Hematology.